Blog

Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA – Streetwise Reports

Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA
Streetwise Reports
Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA Research Report. Source: Streetwise Reports (12/27/17). Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients

2017-12-27 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.